Allurion Technologies (ALUR) said Thursday that initial trial results from the Allurion balloon in combination with semaglutide showed total body weight loss and lean body mass gains.
The company treated 52 patients in the study and the average total body weight loss was 20.3% after eight months while the lean body mass increased by 15%, according to the company.
Shares of the company were up 29% in recent after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。